TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02561923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kcentra, a 4-factor PCC
Description: Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline \[Kcentra saline control or TXA saline control\] on Day 4.
Study: NCT03192319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Zostavax will be administrated by subcutaneous injection
Study: NCT00887835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PERPOS™ PLS
Description: To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
Study: NCT05672446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation with standardized child patient
Description: 49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
Study: NCT01623336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIP 48 (Peginterferon alfa 2b 48kDA)
Description: BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa 2a 40kDA
Description: Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIP 48 (Peginterferon alfa 2b 48kDA)
Description: Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
Study: NCT04683263

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical cream with same composition as Intervention but without active ingredients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fisiocrem
Description: a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
Study: NCT02026076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical lumbar traction
Description: 15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
Study: NCT01893944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: customized applications using virtual and augmented reality to be developed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: customized applications using virtual and augmented reality to be developed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality
Description: customized applications using virtual and augmented reality to be developed.
Study: NCT00851240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTT-1023
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT03510949

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopharyngeal airway or laryngeal mask airway
Description: Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopharyngeal airway or laryngeal mask airway
Description: Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
Study: NCT04502511

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard diagnosis test
Description: Care as usual
Study: NCT04406246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500Mg Oral Tablet
Description: Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.
Study: NCT04797416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FGM infiltration 1 hour group
Description: The sensor is activated immediately after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FGM infiltration 6-hour group
Description: Reactivate the sensor 5 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FGM infiltration 12-hour group
Description: Reactivate the sensor 11 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
Study: NCT01013441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of CD3/CD28 stimulated T cells
Description: Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
Study: NCT04486222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated Transcranial Magnetic Stimulation
Description: Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Transcranial Magnetic Stimulation
Description: Magstim® Super Rapid² Transcranial Magnetic Stimulation System
Study: NCT04174716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX-1197
Description: Until progression or unacceptable toxicity develops
Study: NCT03856541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1403
Description: SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
Study: NCT03597841

Intervention type: DRUG
Intervention: Combination therapy
Description: Patients who are given combination therapy will be allocated to this group.
Study: NCT03485859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
Study: NCT03138473

Intervention type: DIAGNOSTIC_TEST
Intervention: Residual SYNTAX Score
Description: The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score.

Intervention type: DIAGNOSTIC_TEST
Intervention: SYNTAX Revascularization Index
Description: The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-\[rSS/bSS\]) ×100.
Study: NCT04178291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scaler and Gracey currettes
Description: Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler and Gracey currettes
Description: Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder
Description: Air flow PLUS
Study: NCT00928668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744CL)
Description: Olodaterol comparison of low, medium low, medium high and high doses
Study: NCT03929679

Intervention type: DRUG
Intervention: semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT04256655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 1 0.225g
Description: Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 0.75g
Description: Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 2.25 g
Description: Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
Study: NCT02573493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT02589002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Study: NCT01580085

Intervention type: OTHER
Intervention: polysomnography
Description: full night supervised laboratory polysomnography
Study: NCT04405713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: from the onset of symptoms within the first 3 days
Description: ELC within 3 days of onset of ACC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: : from the onset of symptoms within the 4-7 days
Description: ELC 4-7days of onset of ACC
Study: NCT02573493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Study: NCT02573493

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Study: NCT00875992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETN with ASLS
Description: Angle stable locking of ETN using ASLS
Study: NCT03350464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
Study: NCT00875992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETN locked with conventional locking bolts
Description: Conventional surgical procedure
Study: NCT03601026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic counselling
Description: Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
Study: NCT04405713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: from the onset of symptoms beyond 7 days
Description: ELC after 7days of onset of ACC
Study: NCT02067026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aleurone

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01736098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Flux Exercise Intervention
Description: Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
Study: NCT03446365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASMAS
Description: A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education plus child health
Description: Health educator led intervention focused on asthma education and other child health topics.
Study: NCT03767517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: Half of the patients will receive tele-consult program. Tele-consult intervention includes: initial consult and 2 follow up contacts. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Half of the patients will receive usual care. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
Study: NCT03887988

Intervention type: PROCEDURE
Intervention: Primary early reconstruction
Description: Primary surgical reconstruction of the fracture within 3 weeks after injury

Intervention type: OTHER
Intervention: Nonsurgical
Description: Nonsurgical treatment of fracture

Intervention type: PROCEDURE
Intervention: Primary delayed reconstruction
Description: Primary surgical reconstruction of the fracture more than 3 weeks after injury

Intervention type: PROCEDURE
Intervention: Secondary reconstruction
Description: Second surgical reconstruction of the fracture after a primary reconstruction.
Study: NCT04454528

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated radiotherapy
Description: Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
Study: NCT03271333

Intervention type: OTHER
Intervention: lung function tests
Description: Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
Study: NCT04454528

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated radiotherapy
Description: Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab infusion
Description: Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab infusion
Description: Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood and tissue sampling
Description: Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
Study: NCT02041832

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Holter monitoring
Description: Patients undergo 72h Holter monitoring

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable loop recorder
Description: Implantation of loop recorder with follow-up by remote monitoring
Study: NCT00185341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCR1-Antagonist (BAY86-5047, ZK811752)
Description: Given orally in a dose of 600 mg three times daily over 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02308514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryostimulation
Description: pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative care
Description: manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
Study: NCT03000283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line.
Study: NCT04454528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood and tissue sampling
Description: Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood and tissue sampling
Description: Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
Study: NCT02308514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative care
Description: manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
Study: NCT02725684

Intervention type: OTHER
Intervention: Observational study, no intervention
Description: Observational study, no intervention
Study: NCT00969020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote rehabilitation support
Description: An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.